



MLN Matters®



Information for Medicare Fee-For-Service Health Care Professionals

Related Change Request (CR) #: 4053

MLN Matters Number: MM4053

Related CR Release Date: November 1, 2005

Related CR Transmittal #: 738

Effective Date: January 1, 2005

Implementation Date: December 5, 2005

Calendar Year 2005 Payment for Medicare Part B Radiopharmaceuticals Not Paid on a Cost or Prospective Payment Basis

Note: This article was updated on February 16, 2013, to reflect current Web addresses. All other information remains unchanged.

Provider Types Affected

All providers billing carriers, fiscal intermediaries (FIs), or regional home health intermediaries (RHHIs), for Medicare Part B radiopharmaceuticals

Provider Action Needed



STOP – Impact to You

Medicare Part B radiopharmaceuticals payment allowance limits are not subject to the Average Sales Price (ASP), effective January 1, 2005.



CAUTION – What You Need to Know

Effective January 1, 2005, the payment allowance limits for radiopharmaceuticals are determined by the payment methodology in place under Part B as of November 2003.



GO – What You Need to Do

If you require adjustments on radiopharmaceuticals claims processed prior to January 1, 2005, contact your carrier, FI, or RHHI.

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.

Background

In accordance with section 303(c) of the Medicare Modernization Act (MMA) of 2003, effective January 1, 2005, drugs and biologicals not paid on a cost or prospective basis are paid based on the Average Sales Price (ASP).

However, section 303(h) of the MMA of 2003 provided for the continuation of the payment methodology under Medicare Part B, prior to the MMA for radiopharmaceuticals, effective January 1, 2005. Therefore, the payment allowance limits for radiopharmaceuticals are based on the payment methodology under Part B, as of November 2003.

This article and related CR4053 supersede instructions provided in CR3783, transmittal 528, dated April 22, 2005, which stated that Medicare carriers, FIs, and RHHIs will determine payment allowance limits for radiopharmaceuticals based on the ASP. The payment allowance limits for radiopharmaceuticals are not subject to the ASP.

Additional Information

MLN Matters article MM3783, titled "MMA - July 2005 Quarterly Average Sales Price (ASP) Medicare Part B Drug Pricing File, Effective July 1, 2005," can be viewed at <http://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnmattersarticles/downloads/mm3783.pdf> on the CMS website.

The official instruction issued to your carrier/FI/RHHI regarding this change may be viewed by going to <http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R738CP.pdf> on the CMS website.

If you have any questions, please contact your Medicare carrier/FI/RHHI at their toll-free number, which may be found at <http://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/provider-compliance-interactive-map/index.html> on the CMS website.

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.